Digestive Disease Week (DDW) 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

Audrey Abella, 20230530100000

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

New data fortify obeticholic acid role in NASH treatment

Audrey Abella, 20230529100000

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

Vedolizumab prevents postop CD recurrence: new indication likely

Elvira Manzano, 20230524000000

Patients with resected Crohn’s disease (CD) who were treated with the gut-selective α4β7-integrin inhibitor vedolizumab were less likely to have endoscopic signs of recurrence compared with placebo in the Reprevio study presented at DDW 2023.

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

Jairia Dela Cruz, 20230523140000

The novel potassium-competitive acid blocker fexuprazan shows comparable safety and efficacy to the proton pump inhibitor esomeprazole in the treatment of Chinese patients with erosive esophagitis, as shown in the results of a phase III study presented at DDW 2023.

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

Jairia Dela Cruz, 20230522140000

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

Stephen Padilla, 20230522120000

Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.

Digital gut-directed hypnotherapy reduces abdominal pain in IBS patients

Elaine Soliven, 20230520000000

Digital gut-directed hypnotherapy (GDH) programme reduces abdominal pain in adults with irritable bowel syndrome (IBS) compared with digital muscle relaxation (MR), according to a study presented at DDW 2023.

Smoking, asthma tied to worse faecal incontinence symptoms

Stephen Padilla, 20230519120000

More severe faecal incontinence symptoms appear to burden tobacco smokers, reveals a recent study presented at DDW 2023. Tobacco use is also associated with weaker anal sphincter tone and increased rectal hypersensitivity on high-resolution anorectal manometry (HRAM).

Guselkumab safe, effective as induction therapy for UC

Elaine Soliven, 20230517000000

Induction therapy with guselkumab, an interleukin-23 p19 subunit antagonist, results in clinical and symptomatic remission, as well as other endoscopic improvements in patients with moderate-to-severe active ulcerative colitis (UC), according to the QUASAR study presented at DDW 2023.